11
May

08:00 AM PDT

Clinical Operations

Name: Clinical Operations Conferences 2023
Start: 2023-05-11T08:00
End: 2023-05-11T16:50
Location: Hard Rock Hotel San Diego

Strategy Meeting West Coast USA 2023

Jumpstart Clinical Operations on Patient Centricity, Innovation and Efficiency

Hard Rock Hotel San Diego

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered.

Proventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across the West Coast in San Diego, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at Clinical Operations Strategy Meetings.

Adrian Kizewski

Associate Director, Clinical Technology RBQM Technology IQVIA

Ana Krtolica

Senior Vice President, Preclinical Development Oryn Therapeutics

Alejandra Maciel

Vice President, Clinical Affairs Epigenomics

Angela Pietrofeso

Vice President, Clinical Development Operations Oncternal Therapeutics

Arun Sivanandam

Associate Director, Global Clinical Development and Operations Santen Pharmaceuticals

Ben Cadieux

Vice President of Medical Affairs MEI Pharma

Bonne Adams

Chief Operating Officer Tracon Tracon Pharmaceuticals

Ms. Adams joined us as our Vice President of Clinical Operations in August 2006, was promoted to Senior Vice President of Clinical Operations in July 2014, and was promoted to Executive Vice President of Clinical Operations in January 2019. Prior to joining us, Ms. Adams was a Manager of Clinical Operations at Pfizer, Inc., a pharmaceutical corporation, from 2004 to 2006 and at Biogen Idec, Inc., a biotechnology company, from 2002 to 2004. Ms. Adams managed clinical trials at Pfizer that contributed to the 2006 approval of Sutent® in renal cell carcinoma and gastrointestinal stromal tumors, and she managed clinical trials at Biogen Idec that fulfilled post-approval commitments for Zevalin® and Rituxan®. Ms. Adams has managed both early and late-stage oncology studies of small molecules as well as biologics in the areas of lymphoma, lung, colorectal, ovarian, kidney, sarcoma and breast cancers. From 2000 to 2002, she managed non-oncology programs at Quintiles Inc., a service provider for biopharmaceutical and health sciences companies, including studies in the areas of allergy and pulmonary disease. Ms. Adams received a B.A. in Kinesiology and Biology from the University of Colorado and an M.B.A. in Technology Management from The University of Phoenix.

Chad Moore

Co-Founder & Corporate Development Elligo Health Research

Christopher Mizer

President and CEO Vivaris Capital

Daniel Gebremedhin

Partner Flare Capital Partners

Dan Gebremedhin, MD is a Partner at Flare Capital Partners and serves on the Board of Flare portfolio companies Somatus, Eden Health, Positive Development, Vita Health, Oui Health, and Elektra Health. Prior to joining Flare Capital, Dan served as a Medical Director at the Harvard Pilgrim Health Plan. Dan spent over 8 years as a practicing Internal Medicine Physician on the Faculty of the Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School, after completing Internal Medicine Residency at the Massachusetts General Hospital in 2010. Dan served on Former Massachusetts Governor Charlie Baker’s Board of Nursing Home Administrators from 2016 to 2020. He has served as a Senior Health Policy Advisor for the Campaigns of Former Governor Charlie Baker, Former Congressman Joseph Kennedy III and Congressman Jake Auchincloss. Dan earned a BS from the University of California, San Diego, an MD from the Morehouse School of Medicine, and an MBA from the Harvard Business School

Faith Holmes, M.D.

Medical Director, Senior Vice President of Medical Affairs Elligo Health Research

Faith Holmes, M.D., brings more than 30 years of experience in direct patient care, and 11 years of medical practice management to her role as Elligo’s Senior Vice President of Medical Affairs. Her unique perspective plays an important part in building the company’s network of Research Ready physician practices and preparing them to conduct research. Holmes’ rich perspective — including experience in family medicine, hospice, and palliative medicine that spans solo practice and single specialty and multispecialty group practices — allows her to build rapport with study managers, site staff, and investigators, and provide medical and scientific knowledge to support future growth. Holmes has served as the Principal Investigator for interventional, diagnostic device, and observational trials in several therapeutic indications in Elligo’s eSolutions model and at the Elligo Clinical Research Center. She earned her Bachelor of Science degree in chemistry and biology from Trevecca University, her Doctor of Medicine degree from ORU School of Medicine, and is board certified in family medicine and hospice and palliative medicine.

George Ng

Chief Executive Officer Processa Pharmaceuticals

George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing.
Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches.
Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics.
Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.

Jack Florio

Managing Director Weild & Co

Jayasri Vaidyanath

Associate Director, Product Management IQVIA Technologies

Matt Sharma

Senior Clinical Trials Manager Arcturus Therapeutics

Melody Anderson

Executive Director, Clinical Operations Avelas Biosciences

Moya Daniels

SVP, Regulatory Affairs, Clinical Operations and Quality Indapta Therapeutics

Patrick Harrington, Ph.D.

Vice President of Elligo Solutions Elligo Health Research

Dr. Patrick Harrington has over 25 years of scientific research and clinical experience in a broad variety of neuropsychiatric disorders. He has presented his research at professional meetings both nationally and internationally, and co-authored several publications in peer reviewed journals. Patrick has worked on numerous psychiatry trials with sponsors all around the globe. He was the leader for a Clinical Surveillance and Training team where he helped develop pre-enrollment review and a statistical analysis program to assess ongoing patient ratings. He has also created several scales used in clinical trials, collaborated with PIs on randomization decisions within the trial, and helped identify diagnostic and rating problems. In his role with Elligo, Patrick is helping to revolutionize the way clinical trials are designed and run. He holds a doctorate in clinical psychology, with a focus in clinical neuropsychology, from University of Texas at Austin. He won the American Neuropsychiatric Association Young Investigator Award in 1997. For more information, visit <a href="https://www.elligohealthresearch.com/">ElligoHealthResearch.com</a>.

Sagar Vaidya

Vice President of Clinical Development Travere Therapeutics

Sandra Wiley

Director, Translational Sciences MEI Pharma

Wendy Morahan

Senior Director, Clinical Data Analytics IQVIA Technologies

First name	Last name	Job title	Company name	Photo URL	Bio Position
Adrian	Kizewski	Associate Director, Clinical Technology	RBQM Technology IQVIA	https://proventainternational.com/wp-content/uploads/2022/11/Adrian-Kizewski.jpg	Adrian brings expertise spanning R&D and clinical life sciences, business analysis, process design & improvement, and product implementation. Adrian holds an MBA from the McDonough School of Business at Georgetown University in addition to an MSc in Pharmacology from The Johns Hopkins University School of Medicine and a BSc in Biochemistry from Temple University.
Ana	Krtolica	Senior Vice President, Preclinical Development	Oryn Therapeutics	https://proventainternational.com/wp-content/uploads/2022/01/anakrtolica.jpg	Ana completed PhD at University of Rochester. As a postdoc and then, scientist at LBNL and UCSF she explored the influence of microenvironment on carcinogenesis and stem cell phenotype. Ana co-founded and led StemLifeLine, a startup focusing on cell therapy and development of the cancer drug discovery platform. After joining Omniox, Ana developed programs in oncology, ischemic stroke and critical care bringing its technology from early discovery to clinic. She currently leads translational and new indication efforts at Retrotope. Ana received >$5M in grants and serves on NIH Review Boards. She authored multiple patent applications and published >30 research papers.
Alejandra	Maciel	Vice President, Clinical Affairs	Epigenomics	https://proventainternational.com/wp-content/uploads/2023/02/Alejandra-Maciel.jpg	Alejanda has 20 years of experience in Clinical Research, providing strategic and operational leadership for clinical trials for regulated medical device and diagnostic products. Proven ability to develop clinical teams, cultivate stakeholder confidence and execute high pace, high volume, multi-site clinical studies. Hands-on experience in all aspects of clinical trials, from protocol development budget planning to CRO selection and management, site qualification and study execution and clinical study reports. Subject-Matter Expert on ICH-GCP guidelines, CFRs and regulatory requirements for clinical development. Broad background spanning Academic Research, Sponsor and CRO experience. Ample experience at fast-paced start-up companies. Superb ability to adapt and execute
Angela	Pietrofeso	Vice President, Clinical Development Operations	Oncternal Therapeutics	https://proventainternational.com/wp-content/uploads/2023/02/Angela-Pietrofeso.jpg	Angela has over 20 years of extensive global expertise in biopharmaceutical and medical device industries. She has a broad range of therapeutic experience in oncology, ulcerative colitis, cardiovascular medical devices, acute pain, and infectious diseases. Before joining Oncternal, Angela held positions of increasing responsibility Pfizer, Valeant, Metabasis, Cadence Pharmaceuticals, Lithera, W.L Gore & Associates, and Gossamer Bio. Her career highlights include contributions to the successful NDA for Sutent® at Pfizer; the NDA submission for Ofirmev® at Cadence Pharmaceuticals; and the PMA approval of GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) at W.L Gore & Associates. Prior to joining industry Angela worked as a Research Nurse Manager at the Royal Free Hospital (London UK) and as a Registered Nurse in South Africa and UK. Angela holds a Bachelor of Social Science ( Nursing) from University of Natal ( Durban South Africa).
Arun	Sivanandam	Associate Director, Global Clinical Development and Operations	Santen Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2023/04/Arun-Sivanandam.jpg	Arun is a Clinical Operations leader with over 10 years of experience in Site and Sponsor Global Clinical Development. Having transitioned away from a clinical career, Arun worked on Genomics, Cardiology and GI-Immuno-Oncology Investigator-Initiated through Phase 4 cooperative trials at leading Tertiary Care facilities before transitioning to Amgen as a Clinical Development Consultant. He now works as an Associate Director, Global Clinical Development and Operations leading global Phase 1 – 4 studies on innovative Ophthalmology trials at Santen, Bay Area California. Arun has a Bachelors Degree from UC-Riverside, California and a Masters Degree from Wayne State University in Michigan.
Ben	Cadieux	Vice President of Medical Affairs	MEI Pharma	https://proventainternational.com/wp-content/uploads/2023/02/ben-cadieux.jpg
Bonne	Adams	Chief Operating Officer Tracon	Tracon Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2023/02/Bonne-Adams.jpg	Ms. Adams joined us as our Vice President of Clinical Operations in August 2006, was promoted to Senior Vice President of Clinical Operations in July 2014, and was promoted to Executive Vice President of Clinical Operations in January 2019. Prior to joining us, Ms. Adams was a Manager of Clinical Operations at Pfizer, Inc., a pharmaceutical corporation, from 2004 to 2006 and at Biogen Idec, Inc., a biotechnology company, from 2002 to 2004. Ms. Adams managed clinical trials at Pfizer that contributed to the 2006 approval of Sutent® in renal cell carcinoma and gastrointestinal stromal tumors, and she managed clinical trials at Biogen Idec that fulfilled post-approval commitments for Zevalin® and Rituxan®. Ms. Adams has managed both early and late-stage oncology studies of small molecules as well as biologics in the areas of lymphoma, lung, colorectal, ovarian, kidney, sarcoma and breast cancers. From 2000 to 2002, she managed non-oncology programs at Quintiles Inc., a service provider for biopharmaceutical and health sciences companies, including studies in the areas of allergy and pulmonary disease. Ms. Adams received a B.A. in Kinesiology and Biology from the University of Colorado and an M.B.A. in Technology Management from The University of Phoenix.
Chad	Moore	Co-Founder & Corporate Development	Elligo Health Research	https://proventainternational.com/wp-content/uploads/2023/04/Chad-Moore.jpg	Chad Moore brings over 20 years of experience to Elligo Health Research. Prior to co-founding Elligo, he was an investment banker covering the outsourced pharmaceutical services and IT sector for over a decade. Most recently, Moore was a Managing Director at Leerink Partners where he led the firm’s pharmaceutical services and IT investment banking team. In addition, he founded and was the head of the Pharmaceutical Services and IT Investment Banking Practice at Robert W. Baird & Co. Earlier in his career, Moore held positions of increasing responsibilities at PRA International (now PRA Health Sciences) where he worked closely with the executive management team, oversaw PRA’s merger and acquisition activities and assisted in the company’s 2004 initial public offering and subsequent follow-on offering.
Christopher	Mizer	President and CEO	Vivaris Capital	https://proventainternational.com/wp-content/uploads/2023/03/Christopher-Mizer-1.jpg
Daniel	Gebremedhin	Partner	Flare Capital Partners	https://proventainternational.com/wp-content/uploads/2023/04/Dan-Gebremedhin.jpg	Dan Gebremedhin, MD is a Partner at Flare Capital Partners and serves on the Board of Flare portfolio companies Somatus, Eden Health, Positive Development, Vita Health, Oui Health, and Elektra Health. Prior to joining Flare Capital, Dan served as a Medical Director at the Harvard Pilgrim Health Plan. Dan spent over 8 years as a practicing Internal Medicine Physician on the Faculty of the Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School, after completing Internal Medicine Residency at the Massachusetts General Hospital in 2010. Dan served on Former Massachusetts Governor Charlie Baker’s Board of Nursing Home Administrators from 2016 to 2020. He has served as a Senior Health Policy Advisor for the Campaigns of Former Governor Charlie Baker, Former Congressman Joseph Kennedy III and Congressman Jake Auchincloss. Dan earned a BS from the University of California, San Diego, an MD from the Morehouse School of Medicine, and an MBA from the Harvard Business School
Faith	Holmes, M.D.	Medical Director, Senior Vice President of Medical Affairs	Elligo Health Research	https://proventainternational.com/wp-content/uploads/2023/04/Faith-Holmes.jpg	Faith Holmes, M.D., brings more than 30 years of experience in direct patient care, and 11 years of medical practice management to her role as Elligo’s Senior Vice President of Medical Affairs. Her unique perspective plays an important part in building the company’s network of Research Ready physician practices and preparing them to conduct research. Holmes’ rich perspective — including experience in family medicine, hospice, and palliative medicine that spans solo practice and single specialty and multispecialty group practices — allows her to build rapport with study managers, site staff, and investigators, and provide medical and scientific knowledge to support future growth. Holmes has served as the Principal Investigator for interventional, diagnostic device, and observational trials in several therapeutic indications in Elligo’s eSolutions model and at the Elligo Clinical Research Center. She earned her Bachelor of Science degree in chemistry and biology from Trevecca University, her Doctor of Medicine degree from ORU School of Medicine, and is board certified in family medicine and hospice and palliative medicine.
George	Ng	Chief Executive Officer	Processa Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2023/05/George-Ng.jpg	George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing. Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches. Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics. Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.
Jack	Florio	Managing Director	Weild & Co	https://proventainternational.com/wp-content/uploads/2023/03/Jack-Florio.jpg	Jack Florio is a life sciences executive with 50 years of experience across the full range of pharma / biotech companies spanning early-stage company formation through capital formation, operations, and exits. This gives him a unique view of strategy and tactics across the life cycle of many companies. Jack is a Managing Director with Weild & Co. where he works on advisory, capital formation and M&A deals across the sector. He is also an angel investor with NuFund Venture Group and a Partner with Deallus, a global life sciences consultancy. Jack has held operational roles in both small and large companies across the life science space in the US and Europe including a 30 year career with Eli Lilly and Company. Jack has a BS in Pharmaceutical Sciences from Columbia University and an MBA from NYU/Stern School of Business.
Jayasri	Vaidyanath	Associate Director, Product Management	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2023/05/Jayasri-Vaidyanath.jpg	Jayasri has more than 14 years of professional experience in the IT industry, with a focus on Safety and Clinical products. At IQVIA Technologies, Jayasri is responsible for leading, managing and executing Product Strategy for the Site Activation, Training, Site Engagement, and Safety Notifications products. This includes collaborating with sales, solution engineering and delivery teams to provide valuable solutions for customers. She holds a Bachelor of Technology in Information Technology from JNTU India, as well as a Master of Science in Information Sciences from University of North Carolina in Charlotte, NC.
Matt	Sharma	Senior Clinical Trials Manager	Arcturus Therapeutics	https://proventainternational.com/wp-content/uploads/2023/04/Matt-Sharma.jpg
Melody	Anderson	Executive Director, Clinical Operations	Avelas Biosciences	https://proventainternational.com/wp-content/uploads/2023/02/melodyanderson.jpg
Moya	Daniels	SVP, Regulatory Affairs, Clinical Operations and Quality	Indapta Therapeutics	https://proventainternational.com/wp-content/uploads/2023/02/Moya-Daniels.jpg	Ms. Daniels has 30 years industry experience in the fields of Regulatory Affairs, Quality and Clinical Operations. She has led development programs in the regenerative medicine field such as cells, tissues and gene therapy. Ms. Daniels has previously served as Senior Vice President of Regulatory and Quality at Aruvant Therapeutics. Prior held the position of Senior Vice President of Global Quality and GxP Compliance at Orchard Therapeutics, Officer & Head of Regulatory, Quality and Clinical Operations at Histogen, and Vice President of Regulatory Affairs at Fate Therapeutics. Currently, she is SVP of Regulatory Affairs, Quality and Clinical Operations at Indapta Therapeutics. Moya resides here in San Diego with her family, three dogs and a cat.
Patrick	Harrington, Ph.D.	Vice President of Elligo Solutions	Elligo Health Research	https://proventainternational.com/wp-content/uploads/2023/04/Patrick-Harrington.jpg	Dr. Patrick Harrington has over 25 years of scientific research and clinical experience in a broad variety of neuropsychiatric disorders. He has presented his research at professional meetings both nationally and internationally, and co-authored several publications in peer reviewed journals. Patrick has worked on numerous psychiatry trials with sponsors all around the globe. He was the leader for a Clinical Surveillance and Training team where he helped develop pre-enrollment review and a statistical analysis program to assess ongoing patient ratings. He has also created several scales used in clinical trials, collaborated with PIs on randomization decisions within the trial, and helped identify diagnostic and rating problems. In his role with Elligo, Patrick is helping to revolutionize the way clinical trials are designed and run. He holds a doctorate in clinical psychology, with a focus in clinical neuropsychology, from University of Texas at Austin. He won the American Neuropsychiatric Association Young Investigator Award in 1997. For more information, visit ElligoHealthResearch.com.
Sagar	Vaidya	Vice President of Clinical Development	Travere Therapeutics	https://proventainternational.com/wp-content/uploads/2023/02/Sagar-Vaidya.jpg	Dr. Vaidya is a rare disease drug developer and the Vice President of Clinical Development at Travere Therapeutics since 2019. Dr. Vaidya is responsible for overseeing clinical development of the company’s metabolic and neurology pipeline. Previously, Dr. Vaidya served in roles in clinical development at Sangamo Therapeutics and BioMarin Pharmaceuticals, and he remains committed to developing treatments for severe and life-threatening rare diseases. Dr. Vaidya completed his Infectious Diseases fellowship at Massachusetts General Hospital, Internal Medicine/Pediatrics residency at Icahn School of Medicine at Mount Sinai Hospital, and received his M.D./Ph.D. degrees from David Geffen School of Medicine at UCLA.
Sandra	Wiley	Director, Translational Sciences	MEI Pharma	https://proventainternational.com/wp-content/uploads/2023/05/Sandra-Wiley.jpg	Sandy Wiley, PhD is the Director of Translational Sciences at MEI Pharma, Inc, a clinical stage oncology drug development company. Dr Wiley has over 25 years of experience in translational science, drug discovery, and drug development with an emphasis on cancer, autoimmune diseases, neurodegeneration, metabolic diseases, and rare diseases. Her career has included both academic and industry environments. She is part of Clinical R&D at MEI and has close cross-functional engagements with Medical Affairs, Clinical Development, and Clinical Operations
Wendy	Morahan	Senior Director, Clinical Data Analytics	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2022/03/Screen-Shot-2022-03-01-at-15.49.46.png	Wendy has 25+ years experience in the life sciences industry with a career spanning academic research, preclinical drug discovery, and clinical trials, culminating in a focus and passion for delivering technology solutions that help bring treatments to patients faster. Wendy is currently part of the product strategy leadership team for IQVIA Clinical Data Analytics Suite (CDAS), providing both SaaS solutions for the market as well as IQVIA’s internal CRO needs. As part of the CDAS team, Wendy is responsible for strategy, product management leadership, and Go to Market activities.

Adrian Kizewski, Ana Krtolica, Alejandra Maciel, Angela Pietrofeso, Arun Sivanandam, Ben Cadieux, Bonne Adams, Chad Moore, Christopher Mizer, Daniel Gebremedhin, Faith Holmes, M.D., George Ng, Jack Florio, Jayasri Vaidyanath, Matt Sharma, Melody Anderson, Moya Daniels, Patrick Harrington, Ph.D., Sagar Vaidya, Sandra Wiley, Wendy Morahan

See the agenda and facilitator line-up Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead, our interactive Roundtable Discussions let you debate the topics that really matter.

Senior Decision Makers

All our Strategy Meetings are aimed at director-level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard.

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you.

Private and Intimate Networking

Small group discussions, private meetings, networking drink – however you choose to make those important connections, our Strategy Meetings have the solution.